US EditionPenetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
- Hyundai Bioscience presented preclinical results of Penetrium combinations at AACR 2025 in Chicago on May 7, 2025, showing a breakthrough in cancer treatment.
- The research identified extracellular matrix stiffening, causing pseudo-resistance, as the main cause of immunotherapy failure in cold tumors rather than genetic resistance.
- Penetrium remodels the stiffened extracellular matrix to restore infiltration and enable immune cells and drugs to reach tumors, reducing tumor burden and metastasis in various models.
- In a spontaneous canine breast cancer study, the combination of Penetrium and POLYTAXEL reduced the size of primary tumors by 38.7% and decreased metastatic lymph node tumor volume by nearly 79%, indicating a stronger response in metastatic sites and challenging the belief that metastatic cancer cannot be effectively treated.
- These findings confirm Penetrium's readiness for human trials and its potential as a tumor-agnostic cancer therapy platform targeting multiple cancers including TNBC and AML.
Insights by Ground AI
Does this summary seem wrong?
40 Articles
40 Articles
All
Left
2
Center
11
Right
2
Farm Talk Newspaper+38 Reposted by 38 other sources
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
Penetrium™ Achieves Historic BreakthroughOvercoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody TherapyPresented at AACR 2025, Chicago
·Parsons, United States
Read Full Article
Coverage Details
Total News Sources40
Leaning Left2Leaning Right2Center11Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
13%
C 73%
13%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
